FDA approves novel antibiotic EMBLAVEO for cIAI
NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with ...
FiercePharma9d
AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...
Nature1mon
Inhaled aztreonam
In February 2010, aztreonam for inhalation solution (Cayston; Gilead) — an inhalable formulation of the monobactam antibiotic aztreonam and lysine — was approved by the US FDA to improve ...
Contract Pharma9d
AbbVie’s EMBLAVEO Approved by FDA for Treatment of Complicated Intra-Abdominal Infections
Addresses the significant threat of antimicrobial resistance.
Medscape13y
Aztreonam Lysine for Inhalation
Purpose The pharmacology, safety, efficacy, pharmacokinetics, pharmacodynamics, current place in therapy, and potential future therapeutic uses of inhaled aztreonam are reviewed. Conclusion ...